MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ard.2026.03.025

Медицинская библиотека · Annals of the rheumatic diseases · 2026

Response of ultrasound-assessed synovitis to baricitinib, in monotherapy and combined with methotrexate, compared with etanercept in rheumatoid arthritis: a randomised, international, multicentre trial.

Naredo Esperanza, Olivas-Vergara Otto, Borges Pablo E, Recuero-Díaz Sheila, Saraiva Fernando, Martins-Martinho Joana, Costa Filipa, Tenazinha Catarina, Duarte-Monteiro Ana Margarida, Melo Ana Teresa, Guillén-Astete Carlos A, Rodríguez-García Ana, Blanco-Cáceres Boris, Boteanu Alina L, Mera-Varela Antonio, Pérez-Pampín Eva, Golán Yolanda López, Campos Fernández Cristina, Fragío Gíl Jorge Juan, González Mazario Roxana, Steiner Martina, Vergara-Dangond Cristina, Paredes-Romero María Beatriz, Muñoz-Fernández Santiago, Stoenoiu Maria Simona, Toukap Adrien Nzeusseu, Durnez Anne, de Agustín de Oro Juan José, Añez Gustavo A, Coronel Luis, Vicente-Rabaneda Esther F, Castañeda Santos, Llorente Irene, Padovano Ilaria, Gouze Hélène, Leboime Ariane, Breban Maxime, Uson Jaqueline, Villaverde-García Virginia, Miguélez-Sánchez Juan Roberto, Pérez García Carolina, Meraz-Ostiz Juan Antonio, Polino Luciano, Finzel Stephanie, Kanne Anna-Maria, Jandova Ilona, Mediero Aránzazu, Herencia Carmen, Herrero-Beaumont Gabriel, Largo Raquel

СтатьяМногоцентровое исследованиеРандомизированное исследованиеКлиническое исследование IV фазыEquivalence TrialСравнительное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

The primary objective of this randomised, active-controlled, international, multicentre, phase IV clinical trial was to demonstrate noninferiority of the response of ultrasound-assessed synovitis to baricitinib treatment, alone and in combination with methotrexate (MTX), compared with etanercept with MTX in rheumatoid arthritis (RA).

METHODS

Adult patients with active RA and inadequate response to MTX were randomised into 3 parallel treatment groups: baricitinib monotherapy, baricitinib plus MTX, and etanercept plus MTX. The patients underwent clinical, ultrasound, and laboratory assessments at baseline, 4, 12, and 24 weeks. Ultrasound synovitis was scored 0 to 3 in B-mode, Doppler mode, and a combination of both modes. The primary endpoint was the change in the Global European Alliance of Associations for Rheumatology-Outcome Measures in Rheumatology Synovitis Score (GLOESS) for bilateral wrist and metacarpophalangeal joints at week 12. Noninferiority was stated if the changes in the baricitinib groups were above the lower limit of the noninferiority range, defined as 80% of changes observed in the etanercept plus MTX group. Changes in serum concentrations of different mediators were analysed at 24 weeks.

RESULTS

One hundred fifty patients (109 women and 41 men) were randomised. All clinical and ultrasound variables showed significant improvement starting from week 4 across the 3 treatment arms (P < .050). Noninferiority of baricitinib (monotherapy and plus MTX) was confirmed against etanercept with MTX for GLOESS at week 12 (P < .050). Changes in metalloprotease-3 concentration significantly correlated with changes in all ultrasound scores.

CONCLUSIONS

The response of ultrasound-assessed synovitis to baricitinib, alone or in combination with MTX, was noninferior to that of etanercept with MTX.

Для цитирования: Naredo Esperanza, Olivas-Vergara Otto, Borges Pablo E, Recuero-Díaz Sheila, Saraiva Fernando, Martins-Martinho Joana, Costa Filipa, Tenazinha Catarina, Duarte-Monteiro Ana Margarida, Melo Ana Teresa, Guillén-Astete Carlos A, Rodríguez-García Ana, Blanco-Cáceres Boris, Boteanu Alina L, Mera-Varela Antonio, Pérez-Pampín Eva, Golán Yolanda López, Campos Fernández Cristina, Fragío Gíl Jorge Juan, González Mazario Roxana, Steiner Martina, Vergara-Dangond Cristina, Paredes-Romero María Beatriz, Muñoz-Fernández Santiago, Stoenoiu Maria Simona, Toukap Adrien Nzeusseu, Durnez Anne, de Agustín de Oro Juan José, Añez Gustavo A, Coronel Luis, Vicente-Rabaneda Esther F, Castañeda Santos, Llorente Irene, Padovano Ilaria, Gouze Hélène, Leboime Ariane, Breban Maxime, Uson Jaqueline, Villaverde-García Virginia, Miguélez-Sánchez Juan Roberto, Pérez García Carolina, Meraz-Ostiz Juan Antonio, Polino Luciano, Finzel Stephanie, Kanne Anna-Maria, Jandova Ilona, Mediero Aránzazu, Herencia Carmen, Herrero-Beaumont Gabriel, Largo Raquel. Response of ultrasound-assessed synovitis to baricitinib, in monotherapy and combined with methotrexate, compared with etanercept in rheumatoid arthritis: a randomised, international, multicentre trial.. Annals of the rheumatic diseases. 2026. DOI: 10.1016/j.ard.2026.03.025.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.